Megadose Methylprednisolone for Kasabach-Merritt Syndrome
- 1 January 1993
- journal article
- letter
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 10 (2) , 197-198
- https://doi.org/10.3109/08880019309016559
Abstract
Dresse et al1 recently presented their success in the treatment of Kasabach-Merritt syndrome by using prednisone and epsilon amino caproic acid (EACA). Among several approaches in the treatment of this syndrome the authors failed to mention megadose methylprednisolone2,3 (MDMP; daily 30 mg/kg with gradual tapering). Although previously it was used intravenously, recently it is found equally effective when given orally, which is another advantage of this treatment.Keywords
This publication has 7 references indexed in Scilit:
- High doses of methylprednisolone for Kasabach-Merritt syndromeThe Journal of Pediatrics, 1991
- Oral megadose methylprednisolone for childhood acute idiopathic thrombocytopenic purpura [letter]Blood, 1991
- Successful Treatment of Kasabach-Merritt Syndrome with Prednisone and Epsilon-Aminocaproic AcidPediatric Hematology and Oncology, 1991
- High dose intravenous methylprednisolone for Kassabach-Merritt syndromeEuropean Journal of Pediatrics, 1989
- Antifibrinolytic therapy in the management of the kasabach merritt syndromeAmerican Journal of Hematology, 1988
- High-Dose Intravenous Corticosteroid Treatment for Patients with Diamond-Blackfan Syndrome Resistant or Refractory to Conventional TreatmentJournal of Pediatric Hematology/Oncology, 1988
- Treatment of Severe Coagulopathy in the Kasabach-Merritt Syndrome with Aminocaproic Acid and CryoprecipitateNew England Journal of Medicine, 1985